CIK 0001636282 · Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464312787
- Phone
- 6176515940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −8,400 | $87.15 | $732K | 556,640 |
| 2026-09-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −3,700 | $88.06 | $326K | 552,940 |
| 2026-09-01 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −400 | $89.07 | $36K | 552,540 |
| 2026-08-07 | Albers Jeffrey W. Director | Option exercise 10b5-1 | +5,000 | $10.39 | $52K | 5,000 |
| 2026-08-07 | Albers Jeffrey W. Director | Sale 10b5-1 | −5,000 | $104.47 | $522K | 0 |
| 2026-08-07 | Albers Jeffrey W. Director | Sale 10b5-1 | −8,000 | $104.38 | $835K | 19,360 |
| 2026-08-07 | Albers Jeffrey W. Director | Sale 10b5-1 | −10,000 | $104.68 | $1.0M | 9,360 |
| 2026-08-07 | Albers Jeffrey W. Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,000 | 45,000 | ||
| 2026-08-03 | Burrows Scott L Chief Financial Officer | Option exercise 10b5-1 | +7,500 | $14.50 | $109K | 105,494 |
| 2026-08-03 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −5,100 | $95.21 | $486K | 100,394 |
| 2026-08-03 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −2,300 | $96.30 | $221K | 98,094 |
| 2026-08-03 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −100 | $97.10 | $10K | 97,994 |
| 2026-08-03 | Burrows Scott L Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 344,857 | ||
| 2026-08-03 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −800 | $93.97 | $75K | 581,740 |
| 2026-08-03 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −7,157 | $95.10 | $681K | 574,583 |
| 2026-08-03 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −5,635 | $95.93 | $541K | 568,948 |
| 2026-08-03 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −1,392 | $96.82 | $135K | 567,556 |
| 2026-08-03 | Turtle Cameron Chief Executive Officer | Sale 10b5-1 | −16 | $97.46 | $2K | 567,540 |
| 2026-07-01 | Burrows Scott L Chief Financial Officer | Option exercise 10b5-1 | +7,500 | $14.50 | $109K | 105,494 |
| 2026-07-01 | Burrows Scott L Chief Financial Officer | Sale 10b5-1 | −5,775 | $87.55 | $506K | 99,719 |
Page 3 of 11 · 213 trades